Ziopharm Oncology’s Controlled IL-12 Platform Receives EMA’s COMP Positive Recommendation for Orphan Drug Designation to Treat Glioma

Ziopharm Oncology’s Controlled IL-12 Platform Receives EMA’s COMP Positive Recommendation for Orphan Drug Designation to Treat Glioma

Shots:

  • EMA’s Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending Ziopharm’s Controlled IL-12 platform (Ad-RTS-hIL-12 + veledimex) for ODD candidate for the treatment of glioma
  • EMA’s ODD provides regulatory and financial incentives to the company for developing & commercializing therapies for life-threatening diseases no more than five in 10,000 persons in EU and granting an additional 10yrs. period of marketing exclusivity in the EU post approval
  • Ziopharm’s Controlled IL-12 platform is an investigational gene therapy designed to target human interleukin 12 (hIL-12) of the immune system and has received FDA’s FT designation for the treatment of rGBM in adults

Click here to­ read full press release/ article | Ref: Ziopharm | Image: Immuno-Oncology News